News

Stefan Kaufmann Advocates for Advancements in Tuberculosis Control

2nd August 2023

Renowned vaccine researcher, Prof. Dr. Stefan H. E. Kaufmann, recently shared his expertise and insights on tuberculosis in an exclusive interview with ETHealthworld. Prof. Dr. Kaufmann, the inventor of VPM1002,…

VPM helps facilitate fast track designation for Memo Therapeutics AG’s AntiBKV first-in-class treatment for BK virus infection in renal transplant recipients

11th May 2023

VPM helps facilitate fast track designation for Memo Therapeutics AG’s AntiBKV first-in-class treatment for BK virus infection in renal transplant recipients Vakzine Projekt Management GmbH (VPM) announced today that it…

VPM contributes to the successful licensure of the novel malaria vaccine R21/Matrix-M^TM for first use in Ghana

10th May 2023

VPM contributes to the successful licensure of the novel malaria vaccine R21/Matrix-MTM for first use in Ghana. Vakzine Projekt Management GmbH (VPM) is delighted to announce the successful licensing of the…

VPM oversees clinical trial and translational project management – Positive Phase I data of client Memo Therapeutics AG

25th January 2023

VPM oversees clinical trial and translational project management – Positive Phase I data of client Memo Therapeutics AG We are pleased to announce the successful completion of a clinical client…

Press release on the results of a novel tuberculosis vaccine tested in a large phase III trial against severe respiratory infectious diseases

1st December 2022

VPM1002 Vaccination as Prophylaxis Against Severe Respiratory Infectious Diseases 01 December 2022VPM Hannover/Germany and Serum Institute of India Results of a novel tuberculosis vaccine tested in a large phase III trial…

VPM1002 Vaccination as Prophylaxis Against Severe Respiratory Infectious Diseases Including Covid-19 in the Elderly

1st December 2022

VPM1002 Vaccination as Prophylaxis Against Severe Respiratory Infectious Diseases Including Covid-19 in the Elderly We are pleased to announce that our VPM1002 trial, where VPM1002 was given as a prophylaxis…

VPM celebrated its 20 year anniversary during the joint symposium organized by TWINCORE and VPM.

21st September 2022

On 15-16 September 2022, VPM celebrated its 20 year anniversary during the joint symposium organized by TWINCORE and VPM. We are very proud to be able to welcome more than…

Article about VPM’s tuberculosis (TB) vaccine published in the Frankfurter Rundschau

12th August 2022

Article about VPM’s tuberculosis (TB) vaccine published in the Frankfurter Rundschau An article about our tuberculosis (TB) vaccine has been published in the “Frankfurter Rundschau”. For more info click here.

Tuberculosis vaccine candidate VPM1002 safe in HIV- and non-HIV-exposed newborns as study shows

2nd August 2022

The phase I/II clinical trial data with VPM1002BC, a genetically modified bacillus Calmette-Guérin (BCG) strain, has been published in European Urology Oncology. Even three years after the treatment start, almost half of the patients remained recurrence-free. We thank all patients, colleagues, and collaborators for their contributions.

Milestone achieved: end of recruitment for a large African trial against tuberculosis in neonates completed

22nd June 2022

We are pleased to announce that a major milestone in the pivotal phase III trial (trial name: priMe) of the novel tuberculosis vaccine VPM1002 has been achieved with the end of recruitment of all participants.